FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma

Guangbing Zhang, Cuiyu Guo, Yan Wang, Xian‐Da Zhang, Shuang Liu, Wen Qü, Chunxia Chen, Lingli Yan, Zhouning Yang, Zhixiong Zhang, Xiaohua Jiang, Xiaofeng Chen, Hong Liu, Qinhuai Lai, Xian Wei, Ying Lu, Shengyan Zhao, Han Deng, Yuxi Wang, Lin Yu, Hongbin Yu, Yu Wu, Zhaoming Su, Pengyu Chen, Ziqing Ren, Meng Yu, Feng Qu, Yong Luo, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang, Yu MengJournal of Hematology & Oncology 2022 · DOI · OpenAlex

Abstract

Anti-CD38 monoclonal antibodies (mAbs) like daratumumab and isatuximab have revolutionized the treatment of multiple myeloma (MM). However, their clinical utility is hampered by CD38 expression on red blood cells (RBCs), leading to an "antigen sink" and interference with blood compatibility testing. We report the development of FTL004, a novel humanized anti-CD38 mAb that exhibits negligible binding to RBCs while maintaining high affinity for malignant cells. FTL004 demonstrates superior pro-apoptotic activity and enhanced antibody-dependent cellular cytotoxicity (ADCC) through Fc engineering. Structural analysis via cryo-electron microscopy reveals a unique epitope that distinguishes FTL004 from existing therapies. These findings suggest FTL004 is a promising candidate for treating MM and non-Hodgkin lymphoma with an improved safety and pharmacokinetic profile.

Introduction

The cell surface glycoprotein CD38 is highly expressed in multiple myeloma and various lymphomas, making it an ideal therapeutic target. While current anti-CD38 mAbs have shown significant success, they suffer from off-target binding to RBCs. This binding necessitates high dosing to overcome the "antigen sink" and complicates pre-transfusion testing due to RBC agglutination. FTL004 was designed to address these limitations by targeting a unique epitope that is less accessible or less prevalent on healthy RBCs, providing a "molecular stealth" advantage.

Methods

FTL004 is a humanized IgG1κ antibody. To maximize the immune system's "kill signal," the Fc domain was engineered with specific mutations (S240D/I333E) to increase affinity for Fcγ receptors on Natural Killer (NK) cells, boosting Antibody-Dependent Cellular Cytotoxicity (ADCC). The study employed surface plasmon resonance (SPR) for affinity measurements and flow cytometry for cell binding assays. Structural mapping was performed using Cryo-electron microscopy (Cryo-EM) at a resolution of 3.86 Å to identify the exact binding interface on the CD38 protein.

Results

FTL004 demonstrated high binding affinity (KD = 2.55 nM) comparable to clinical standards (Fig. 1a). Crucially, flow cytometry revealed that FTL004 binding to human RBCs was virtually undetectable, even at concentrations up to 30 μg/mL, whereas daratumumab and isatuximab showed significant binding (Fig. 1c). Furthermore, FTL004 did not induce RBC agglutination in indirect antiglobulin tests, potentially solving the blood transfusion interference issue common with current therapies (Fig. 1d).

Characterization of FTL004 binding, RBC interaction, and structural epitope mapping.

Structural analysis identified two epitope centers for FTL004 on CD38. One center (91TQTV94) partially overlaps with the isatuximab epitope, while the other is entirely unique. Notably, FTL004 shares no common binding residues with daratumumab (Fig. 1h-j). This unique binding profile likely underlies the observed RBC-sparing effect.

Functionally, FTL004 induced significantly higher rates of direct apoptosis in MM cell lines compared to isatuximab. For instance, in RPMI 8226 cells, FTL004 induced 55% early apoptosis compared to just 20% for isatuximab. The engineered Fc domain resulted in high ADCC potency, with EC50 values in the low ng/mL range. In vivo, FTL004 effectively inhibited tumor growth in lymphoma and myeloma xenograft models compared to saline controls.

Discussion and Conclusion

FTL004 represents a significant advancement in anti-CD38 therapy. By avoiding RBC binding, it potentially eliminates the need for high-dose "loading" and simplifies clinical management of patients requiring blood transfusions. The combination of enhanced direct apoptosis and boosted ADCC suggests superior anti-tumor efficacy. While some NK cell depletion was observed—a common trait of anti-CD38 therapies—the levels were considered acceptable (Fig. 1g).

In conclusion, FTL004 is a potent, next-generation anti-CD38 mAb with a unique structural footprint. Its ability to discriminate between malignant cells and healthy RBCs, combined with enhanced immune-mediated killing, makes it a highly promising candidate for the treatment of CD38-positive hematological malignancies. Future clinical trials will be essential to confirm if these preclinical advantages translate into superior outcomes for patients.

Summary updated

Abstract

Anti-CD38 monoclonal antibodies (mAbs), daratumumab, and isatuximab have represented a breakthrough in the treatment of multiple myeloma (MM). Recently, CD38-based mAbs were expected to achieve increasing potential beyond MM, which encouraged us to develop new anti-CD38 mAbs to meet clinical needs. In this study, we developed a novel humanized anti-CD38 antibody, FTL004, which exhibited enhanced pro-apoptotic ability and negligible binding to red blood cells (RBCs). FTL004 presented a better ability to induce direct apoptosis independent of Fc-mediated cross-linking against lymphoma and MM cell lines as well as primary myeloma cells derived from MM patients. For instance, FTL004 induced RPMI 8226 cells with 55% early apoptosis cells compared with 20% in the isatuximab-treated group. Of interest, FTL004 showed ignorable binding to CD38 on human RBCs in contrast to tumor cells, even at concentrations up to 30 μg/mL. Furthermore, with an engineered Fc domain, FTL004 displayed stronger antibody-dependent cellular cytotoxicity (ADCC) against CD38+ malignant cells. In vivo MM and non-Hodgkin lymphoma tumor xenograft models showed that FTL004 possessed an effective anti-tumor effect. Cryo-electron microscopy structure resolved two epitope centers of FTL004 on CD38: one of which was unique while the other partly overlapped with that of isatuximab. Taken together, FTL004 distinguishes it from other CD38 targeting mAbs and represents a potential candidate for the treatment of MM and non-Hodgkin lymphoma.
BibTeX
@article{zhang2022ftl,
  author = {Guangbing Zhang and Cuiyu Guo and Yan Wang and Xian‐Da Zhang and Shuang Liu and Wen Qü and Chunxia Chen and Lingli Yan and Zhouning Yang and Zhixiong Zhang and Xiaohua Jiang and Xiaofeng Chen and Hong Liu and Qinhuai Lai and Xian Wei and Ying Lu and Shengyan Zhao and Han Deng and Yuxi Wang and Lin Yu and Hongbin Yu and Yu Wu and Zhaoming Su and Pengyu Chen and Ziqing Ren and Meng Yu and Feng Qu and Yong Luo and Lantu Gou and Qing Li and Ying Huang and Fanxin Ma and Jinliang Yang and Yu Meng},
  title = {{FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma}},
  journal = {Journal of Hematology \& Oncology},
  year = {2022},
  doi = {10.1186/s13045-022-01395-0},
}
Figure